– Texas Cardiac Arrhythmia Institute at St. David’s Medical Center to host an international virtual symposium on complex cardiac arrhythmias EPLive 2020, a two-day educational conference, uses live cases as a primary teaching tool AUSTIN, Texas , Nov. 24, 2020 / PRNewswire / – On December 3-4, 2020, the Texas Cardiac […]
Rhythm
FDA Clears First of its Kind Algorithm Suite for Personal ECG
AliveCor Paving the Way For A New Generation of AI-Powered Remote Cardiology MOUNTAIN VIEW, Calif., Nov. 23, 2020 /PRNewswire/ — AliveCor, the leader in AI-based personal ECG technology and provider of enterprise cardiology solutions, today announced that the US FDA had given clearance to the company’s next generation of interpretive ECG algorithms. “Kardia […]
VitalConnect Announces the Launch of VitalPatch® RTM, a First-of-its-kind Extended Holter Technology for Cardiac Monitoring
In combination with its newly opened independent diagnostic testing facility, VitalConnect is advancing how patients are monitored for cardiac arrhythmias SAN JOSE, Calif.–(BUSINESS WIRE)–VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, announced today it has launched its VitalPatch RTM cardiac monitoring solution for patients who require extended Holter […]
The New England Journal of Medicine: Medtronic Cryoablation is a Superior Treatment Option for Symptomatic Paroxysmal Atrial Fibrillation Compared to Drug Therapy
Results from Three Studies Show Medtronic Cryoablation is Superior to Drug Therapy for First-Line Treatment DUBLIN, Nov. 16, 2020 /PRNewswire(opens new window)/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the primary results of the Medtronic-sponsored STOP AF First clinical trial have been published in the New England […]
Zio by iRhythm Detects Previously Undiagnosed Atrial Fibrillation and Helps to Prevent Hospitalizations, Stroke, and Death as a Result
Three-Year Study Results Presented at 2020 American Heart Association Scientific Sessions Zio Supports Better Healthcare Utilization Rates and Patient Outcomes With Ambulatory Cardiac Monitoring SAN FRANCISCO, Nov. 16, 2020 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, […]
InCarda Therapeutics Presents Positive New Data from Phase 2 Study of InRhythm™ in Patients with Paroxysmal Atrial Fibrillation at American Heart Association Scientific Sessions 2020
Data Demonstrate Achievement of Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Study Findings Provide Proof of Concept for First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF) Provides Roadmap for Start of Pivotal Phase 3 in Medically Supervised Setting in 2021 SAN FRANCISCO, Nov. 13, 2020 (GLOBE NEWSWIRE) — InCarda Therapeutics, Inc. (“InCarda”), a […]
iRhythm Technologies Announces Data from mSToPS Clinical Trial to be Presented in a Late-Breaking Scientific Session at American Heart Association 2020
iRhythm to Host Webcast to Discuss Outcomes on Monday, November 16, 2020 SAN FRANCISCO, Nov. 13, 2020 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that 3-year clinical outcomes in a nationwide, randomized, pragmatic […]
Acceleron Presents New Data from the PULSAR Phase 2 Trial, Preclinical Research on Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association (AHA) Scientific Sessions
– Treatment with sotatercept in the ongoing PULSAR Phase 2 trial was associated with improvements in cardiac and pulmonary function at week 24 – – Presentation of echocardiography data from the PULSAR trial received AHA’s “Cardiopulmonary Best Abstract” Award – – Preclinical research shows sotatercept inhibits cardiac remodeling, restores function […]
Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
− Patients Receiving Investigational ALN-AGT Experienced Dose-Dependent Reductions in Blood Pressure, Confirming Potential for RNAi-Mediated Angiotensinogen (AGT) Silencing as a Novel Therapeutic Approach for Hypertension – − Durable AGT Knockdown Through 12 Weeks Supports a Once Quarterly or Potentially Less Frequent Dosing Regimen – − ALN-AGT Generally Well Tolerated, with […]
Kardium Performs First Cases with the Globe® Positioning System
New 3D mapping and navigation feature allows for high-definition mapping of the full atrium VANCOUVER, British Columbia–(BUSINESS WIRE)–Kardium is pleased to announce the first clinical use of the Globe Positioning System (GPS™) – the new 3D mapping and navigation feature of its flagship product, the Globe® Mapping and Ablation System. […]



